{
  "docId": "019de076-2351-76a2-9dc5-1c75bf1dd158",
  "docSlug": "905d9ceaf5cb608feb86b583a8401e54",
  "documentTitle": "AstraZeneca | Results Presentation Deck | 45 slides",
  "authorId": "astrazeneca",
  "authorName": "AstraZeneca",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 15,
  "pageCount": 45,
  "prevPage": 14,
  "nextPage": 16,
  "slideType": "key_takeaways",
  "function": "summarize",
  "density": "dense",
  "nDataPoints": 10,
  "notes": "The slide uses a navigation bar at the top to indicate the current section (Oncology).",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-2351-76a2-9dc5-1c75bf1dd158/15",
  "deckHref": "/decks/019de076-2351-76a2-9dc5-1c75bf1dd158",
  "deckJsonHref": "/decks/019de076-2351-76a2-9dc5-1c75bf1dd158.json",
  "deckAnchorHref": "/decks/019de076-2351-76a2-9dc5-1c75bf1dd158#slide-15",
  "components": [
    {
      "bbox": {
        "h": 0.6,
        "w": 0.42,
        "x": 0.03,
        "y": 0.25
      },
      "kind": "chart",
      "text": "Oncology 9M 2023 $13.5bn, +20%",
      "attrs": null,
      "subkind": "bar-stacked",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "682fecdf-f6fd-4abf-ad40-a6878a20c6d1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.5,
        "x": 0.46,
        "y": 0.25
      },
      "kind": "list",
      "text": "Q3 2023: key dynamics",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4d65f3ef-5ba7-4adb-bbe6-d9f627223494",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.9,
        "x": 0.03,
        "y": 0.9
      },
      "kind": "source-note",
      "text": "All growth rates at CER. CER = constant exchange rates; NRDL = National Reimbursement Drug List; PS = Product Sales; EU = Europe; ERoW = Established Rest of World; EM = Emerging Markets; CN = China; 2L = 2nd-line; OC = ovarian cancer; PARPi = poly (ADP-ribose) polymerase inhibitor; BTKi = bruton tyrosine kinase inhibitor; 1L = 1st-line; r/r CLL = relapsed/refractory chronic lymphocytic leukaemia; DB03 = DESTINY-Breast03; DB04 = DESTINY-Breast04; DL02 = DESTINY-Lung02; SLL = small lymphocytic lymphoma. Collaboration partners: Daiichi Sankyo (Enhertu), Merck & Co., Inc. (Lynparza).",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4b266399-2829-4f60-9380-a4b876350281",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.75,
        "x": 0.03,
        "y": 0.13
      },
      "kind": "title",
      "text": "Total Revenue +20% in 9M 2023 fueled by strong global demand growth",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "da7d1ab2-186b-4774-bc1e-d60cbe5e6de3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.45,
        "x": 0.03,
        "y": 0.06
      },
      "kind": "title",
      "text": "Oncology – 9M and Q3 2023",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2daf5908-c4e4-4843-97ab-39cd8c906825",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Big Idea Formula",
      "slug": "big-idea-formula",
      "agent": "Storyteller",
      "layer": "slide",
      "matchId": "550317e6-93bb-4f42-9eee-c6ecc8eac2e2",
      "evidence": "The slide presents a clear and concise message with a big number and a chart.",
      "confidence": 0.5
    },
    {
      "name": "Chart Selection Guide",
      "slug": "chart-selection-guide",
      "agent": "Designer",
      "layer": "slide",
      "matchId": "446cbdbd-50ca-40cb-bf8e-bde3b3c429ef",
      "evidence": "The use of a stacked bar chart effectively communicates the growth of Oncology revenue.",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 20,
      "from": 15,
      "beatId": "88166dd9-a0d1-4ffb-ac51-e141aedff5d2",
      "arcName": "Monroe's Motivated Sequence",
      "arcSlug": "monroes-sequence",
      "beatName": "Satisfaction",
      "beatSlug": "monroes-sequence-satisfaction",
      "evidence": "Key takeaways and highlights from Oncology and BioPharmaceuticals",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [
    {
      "to": 20,
      "from": 5,
      "name": "Logic Chain",
      "slug": "01-logic-chain",
      "bestFor": "Skeptical audiences, controversial recommendations, rigorous analysis",
      "matchId": "4272c71f-edd6-48f7-a353-789a42575177",
      "evidence": "The document walks through a logical chain of financial performance, portfolio evolution, and R&D highlights",
      "position": 0,
      "objective": "How AstraZeneca's diversified portfolio drives growth",
      "structure": "Premise 1 (Accepted truth) -> Premise 2 (Observed fact) -> Therefore... (Inevitable conclusion)",
      "confidence": 0.7,
      "description": "Build an airtight chain of logic where each premise leads inevitably to the conclusion"
    },
    {
      "to": 20,
      "from": 13,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "f01e337f-a074-4bb0-a0a6-8afab8af6ed6",
      "evidence": "The document highlights the potential consequences of inaction in not leveraging technology for better patient outcomes",
      "position": 1,
      "objective": "The importance of harnessing technology to deliver better patient outcomes",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}